New drug aims to shrink rare adrenal tumors
NCT ID NCT07714551
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This phase 2 trial tests an oral drug called zanzalintinib in people with metastatic pheochromocytoma or paraganglioma that cannot be surgically removed and is growing. The study measures how many participants see their tumors shrink or stop growing. All participants take the drug daily, and researchers track response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanzalintinib (also known as XL092), an oral drug taken daily
- What this could lead to
- If successful, this could offer a new treatment option for people with these rare, hard-to-treat tumors.
- What could go wrong
- This is a small, early-phase trial with only 14 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital (BWH)
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioated molecule shrink untreatable neuroblastoma?
- Could a smartphone replace clinic visits for rare tumor survivors?
- Could a cancer drug quiet overactive adrenal hormones? a new study investigates.
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
- New scan could spot hidden tumors more accurately
- New PET scan agent aims to better detect rare tumors